Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $26.6 million.

  • Lineage Cell Therapeutics' Gains from Investment Securities changed N/A to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year increase of 9663333.33%. This contributed to the annual value of -$2.1 million for FY2024, which is 404074.07% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Gains from Investment Securities is $26.6 million.
  • Lineage Cell Therapeutics' 5-year Gains from Investment Securities high stood at $26.6 million for Q3 2025, and its period low was -$2.3 million during Q1 2025.
  • Over the past 4 years, Lineage Cell Therapeutics' median Gains from Investment Securities value was $18000.0 (recorded in 2023), while the average stood at $4.0 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Gains from Investment Securities surged by 7835.82% in 2021 and then plummeted by 1677692.31% in 2024.
  • Quarter analysis of 4 years shows Lineage Cell Therapeutics' Gains from Investment Securities stood at -$29000.0 in 2021, then skyrocketed by 144.83% to $13000.0 in 2023, then crashed by 16776.92% to -$2.2 million in 2024, then skyrocketed by 1324.95% to $26.6 million in 2025.
  • Its Gains from Investment Securities stands at $26.6 million for Q3 2025, versus $12.7 million for Q2 2025 and -$2.3 million for Q1 2025.